UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016678
Receipt number R000019355
Scientific Title Analysis of tumor immune microenvironments and host immune responses in cancer patients
Date of disclosure of the study information 2015/03/02
Last modified on 2021/04/06 21:31:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Analysis of tumor immune microenvironments and host immune responses in cancer patients

Acronym

Analysis of tumor immune microenvironments and host immune responses

Scientific Title

Analysis of tumor immune microenvironments and host immune responses in cancer patients

Scientific Title:Acronym

Analysis of tumor immune microenvironments and host immune responses

Region

Japan


Condition

Condition

malignancy

Classification by specialty

Medicine in general Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

analysis of tumor immune microenvironment and host immune responses against cancer antigen in cancer patients

Basic objectives2

Bio-availability

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1) Investigation of methods and biomarker for the prognosis of malignacy using immune factors

Key secondary outcomes

1)prospective
analysis of tumor immune microenvironmens and host immune responses
: os,pfs,rr

2)investigation of methods and biomarker for the prognosis of malignacy using immune factors: os,pfs,rr


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.ECOG performance status 0-2
2.Under the hematological toxicity of Grade3

Key exclusion criteria

Sever complications

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name Mikio
Middle name
Last name Oka

Organization

Kawasaki Medical School

Division name

Department of Immuno-Oncology

Zip code

701-0192

Address

577 Matsusima, Kurashiki

TEL

086-462-1111

Email

resp@med.kawasaki-m.ac.jp


Public contact

Name of contact person

1st name Koji
Middle name
Last name Kurose

Organization

Kawasaki Medical School

Division name

Respiratory Medicine

Zip code

701-0192

Address

577 Matsusima, Kurashiki

TEL

086-462-1111

Homepage URL


Email

kuro-ko.66@med.kawasaki-m.ac.jp


Sponsor or person

Institute

Kawasaki Medical School

Institute

Department

Personal name



Funding Source

Organization

Ministry of Education, Culture, Sports, Science and Technology

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB of Kawasaki Medical School

Address

577 Matsushima, Kurashiki, Okayama

Tel

086-462-1111

Email

kmsrec@med.kawasaki-m.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 03 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2015 Year 04 Month 13 Day

Date of IRB

2015 Year 04 Month 13 Day

Anticipated trial start date

2015 Year 04 Month 13 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry

2023 Year 03 Month 31 Day

Date trial data considered complete

2023 Year 03 Month 31 Day

Date analysis concluded

2023 Year 03 Month 31 Day


Other

Other related information

prospective
analysis of tumor immune microenvironmens and host immune responses
: os,pfs,rr

investigation of methods and biomarker for the prognosis of malignacy using immune factors: os,pfs,rr


Management information

Registered date

2015 Year 03 Month 02 Day

Last modified on

2021 Year 04 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019355


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name